Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 747PARP inhibition in cancer therapyBRCA gene mutations in cancerDNA Repair Mechanisms

The DOI matches its Crossref record; 98 of the 100 references it cites were found in a registry or an index.

A decade of clinical development of PARP inhibitors in perspective

Open access
Mateo, J., Lord, C.J., Serra, V., Tutt, A., Balmaña, J., Castroviejo-Bermejo, M., Cruz, C., Oaknin, A., Kaye, S.B., de Bono, J.S.·2019·Annals of Oncology

Abstract

Genomic instability is a hallmark of cancer, and often is the result of altered DNA repair capacities in tumour cells. DNA damage repair defects are common in different cancer types; these alterations can also induce tumour-specific vulnerabilities that can be exploited therapeutically. In 2009, a first-in-man clinical trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib clinically validated the synthetic lethal interaction between inhibition of PARP1, a key sensor of DNA damage, and BRCA1/BRCA2 deficiency. In this review, we summarize a decade of PARP inhibitor clinical development, a work that has resulted in the registration of several PARP inhibitors in breast (olaparib and talazoparib) and ovarian cancer (olaparib, niraparib and rucaparib, either alone or following platinum chemotherapy as maintenance therapy). Over the past 10 years, our knowledge on the mechanism of action of PARP inhibitor as well as how tumours become resistant has been extended, and we summarise this work here. We also discuss opportunities for expanding the precision medicine approach with PARP inhibitors, identifying a wider population who could benefit from this drug class. This includes developing and validating better predictive biomarkers for patient stratification, mainly based on homologous recombination defects beyond BRCA1/BRCA2 mutations, identifying DNA repair deficient tumours in other cancer types such as prostate or pancreatic cancer, or by designing combination therapies with PARP inhibitors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdz192

Cites

98 of 98 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Proposed mechanisms for PARPi activity in HRR-deficient cells. PARP inhibition impairs repair of single strain breaks (SSBs) by disrupting the base excision repair (BER) pathway and also causing PARP1 trapping by inhibiting auto-PARylation and/or PARP release from DNA. These result in unresolved DNA double-strand breaks (DSBs) that in homologous recombination repair (HRR)-deficient cells lead to cell death.
Figure 1. Proposed mechanisms for PARPi activity in HRR-deficient cells. PARP inhibition impairs repair of single strain breaks (SSBs) by disrupting the base excision repair (BER) pathway and also causing PARP1 trapping by inhibiting auto-PARylation and/or PARP release from DNA. These result in unresolved DNA double-strand breaks (DSBs) that in homologous recombination repair (HRR)-deficient cells lead to cell death.CC BY-NC · PubMed Central
Figure 2. Described mechanisms of secondary resistance to PARP inhibitors. The potential mechanisms of PARPi resistance can be classified in three main groups: (i) those that result in restoration of homologous recombination repair (HRR), (ii) those leading to mitigation of replication stress (RS) commonly together with slower cell cycle progression, and (iii) other mechanisms not directly related with an HRR or RS pathway but that still alter the response to PARPi, such as mutations in PARP1 or drug effluxion pumps.
Figure 2. Described mechanisms of secondary resistance to PARP inhibitors. The potential mechanisms of PARPi resistance can be classified in three main groups: (i) those that result in restoration of homologous recombination repair (HRR), (ii) those leading to mitigation of replication stress (RS) commonly together with slower cell cycle progression, and (iii) other mechanisms not directly related with an HRR or RS pathway but that still alter the response to PARPi, such as mutations in PARP1 or drug effluxion pumps.CC BY-NC · PubMed Central
Figure 3. Rational combinations of PARPi with other targeted agents. Hypothesis-driven combinations with PARP inhibitors are summarized; (A) combinations of PARPi with other compounds targeting alternatives DDR nodes aim to maximize accumulation DNA damage during G1 and S phases of the cell cycle, together with preventing its repair during G2 by minimizing the time to repair. This would lead to accumulation of DNA damage during mitosis and cell death. (B) Combinations with drugs targeting other biological pathways which have been shown to be modulated and/or to modulate HRR function, such as the PI3K/AKT pathway, RAS, VEGFR, and AR signalling pathways. (C) Rationale for developing PARPi-immunotherapy combinations; defects in DDR might increase genomic instability, leading to accumulation of mutations and, putatively, increased neoantigen production and T-cell activation. An alternative hypothesis supporting PARPi-immunotherapy combinations is the accumulation of cytosolic DNA induced by DDR defects, which would activate the innate immune system through the cGAS-STING pathway, inducing interferon-mediated response. This pro-inflammatory cascade would result in activation of NK cells and macrophages and the infiltration, proliferation and antitumour response of CD4+ and CD8+ T cells into the tumour. Paradoxically, the STING pathway also activates the expression of PD-L1 in tumour cells, therefore limiting the cytotoxic immune response, but potentially rendering the tumour sensitive to PD-L1 blockade (DC, dendritic cell; M∅, macrophage; NK, natural killer cell; Treg, regulatory T cell).
Figure 3. Rational combinations of PARPi with other targeted agents. Hypothesis-driven combinations with PARP inhibitors are summarized; (A) combinations of PARPi with other compounds targeting alternatives DDR nodes aim to maximize accumulation DNA damage during G1 and S phases of the cell cycle, together with preventing its repair during G2 by minimizing the time to repair. This would lead to accumulation of DNA damage during mitosis and cell death. (B) Combinations with drugs targeting other biological pathways which have been shown to be modulated and/or to modulate HRR function, such as the PI3K/AKT pathway, RAS, VEGFR, and AR signalling pathways. (C) Rationale for developing PARPi-immunotherapy combinations; defects in DDR might increase genomic instability, leading to accumulation of mutations and, putatively, increased neoantigen production and T-cell activation. An alternative hypothesis supporting PARPi-immunotherapy combinations is the accumulation of cytosolic DNA induced by DDR defects, which would activate the innate immune system through the cGAS-STING pathway, inducing interferon-mediated response. This pro-inflammatory cascade would result in activation of NK cells and macrophages and the infiltration, proliferation and antitumour response of CD4+ and CD8+ T cells into the tumour. Paradoxically, the STING pathway also activates the expression of PD-L1 in tumour cells, therefore limiting the cytotoxic immune response, but potentially rendering the tumour sensitive to PD-L1 blockade (DC, dendritic cell; M∅, macrophage; NK, natural killer cell; Treg, regulatory T cell).CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 100 references

Cited by

See all 747

Metadata

Authors
Mateo, J., Lord, C. J., Serra, V., Tutt, A., Balmaña, J., Castroviejo-Bermejo, M., Cruz, C., Oaknin, A., Kaye, S. B., & de Bono, J. S.
Affiliations
  • Vall d'Hebron Hospital Universitari (ES)
  • Institute of Cancer Research (GB)
  • Vall d'Hebron Institute of Oncology (ES)
  • Royal Marsden NHS Foundation Trust (GB)
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2019-09
Volume
30
Issue
9
Pages
1437-1447
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2951058429
Cited by
743
References
100
Citations by year
2026: 58 · 2025: 123 · 2024: 81 · 2023: 123 · 2022: 145 · 2021: 128 · 2020: 77 · 2019: 8
FWCI
8.58
Type
journal article
Language
en
Open access
Licence
Locations
  • Annals of Oncology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Research Portal (King's College London) (submittedVersion, other-oa)
Funders
  • Prostate Cancer Foundation
  • Instituto de Salud Carlos III
  • FERO Foundation
  • Asociación Española Contra el Cáncer
  • AECC-JP Barcelona
  • Cancer Research UK
  • Department of Health (C12540/A25128)
  • NHS funding
  • NIHR Biomedical Research Centre
  • Institute of Cancer Research
  • National Institute for Health Research
  • NIHR
Topics
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
Keywords
PARP inhibitors, olaparib, talazoparib, niraparib, rucaparib, synthetic lethality, DNA repair deficiency, genomic instability, breast cancer, ovarian cancer, maintenance therapy, platinum-based chemotherapy, PARP inhibitor resistance, predictive biomarkers, homologous recombination defects, precision medicine, prostate cancer, pancreatic cancer, combination therapy
MeSH terms
Poly(ADP-ribose) Polymerase Inhibitors, Poly (ADP-Ribose) Polymerase-1, Breast Neoplasms, Female, Humans, Indazoles, Indoles, Ovarian Neoplasms, Phthalazines, Piperazines, Piperidines, BRCA1 Protein, BRCA2 Protein, Genomic Instability

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A decade of clinical development of PARP inhibitors in perspective. https://app.cochat.ai/papers/10.1093/annonc/mdz192
The paper
Mateo, J., Lord, C. J., Serra, V., Tutt, A., Balmaña, J., Castroviejo-Bermejo, M., Cruz, C., Oaknin, A., Kaye, S. B., & de Bono, J. S. (2019). A decade of clinical development of PARP inhibitors in perspective. Annals of Oncology. https://doi.org/10.1093/annonc/mdz192

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.